Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Eijk, Tessa Kliest, C. Mcdermott, K. Roes, P. Damme, A. Chiò, Markus Weber, C. Ingre, P. Corcia, M. Povedano, Evy Reviers, M. Es, A. Al-Chalabi, O. Hardiman, L. Berg (2020)
TRICALS: creating a highway toward a cureAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21
M. Ryan, M. Heverin, Mark Doherty, N. Davis, Emma Corr, A. Vajda, N. Pender, R. McLaughlin, O. Hardiman (2018)
Determining the incidence of familiality in ALSNeurology: Genetics, 4
O. Hardiman, L. Berg, M. Kiernan (2011)
Clinical diagnosis and management of amyotrophic lateral sclerosisNature Reviews Neurology, 7
C. Johnston, Biba Stanton, Biba Stanton, M. Turner, R. Gray, Ashley Blunt, David Butt, Mary‐Ann Ampong, Christopher Shaw, Christopher Shaw, P. Leigh, P. Leigh, A. Al-Chalabi, A. Al-Chalabi (2006)
Amyotrophic lateral sclerosis in an urban settingJournal of Neurology, 253
(2018)
Determining the incidence of familiality in ALS: a study of temporal trends in Ireland from 1994 to 2016, 4
A. Ludolph, J. Brettschneider, Jochen Weishaupt (2012)
Amyotrophic lateral sclerosis.Current opinion in neurology, 25 5
J. Olesen, A. Gustavsson, Mikael Svensson, H. Wittchen, B. Jönsson (2012)
The economic cost of brain disorders in EuropeEuropean Journal of Neurology, 19
O. Hardiman, A. Al-Chalabi, A. Chiò, Emma Corr, G. Logroscino, W. Robberecht, P. Shaw, Z. Simmons, L. Berg (2017)
Amyotrophic lateral sclerosisNature Reviews Disease Primers, 3
C. Johnston, B. Stanton, M. Turner, R. Gray, Ashley Blunt, David Butt, Mary‐Ann Ampong, C. Shaw, P. Leigh, A. Al-Chalabi (2006)
Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London.Journal of neurology, 253 12
Stephen Goutman, O. Hardiman, A. Al-Chalabi, A. Chiò, M. Savelieff, M. Kiernan, E. Feldman (2022)
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosisThe Lancet Neurology, 21
R. Mead, N. Shan, H. Reiser, F. Marshall, P. Shaw (2022)
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translationNature Reviews. Drug Discovery, 22
M. O’Brien, T. Burke, M. Heverin, A. Vajda, R. McLaughlin, J. Gibbons, S. Byrne, Marta Pinto-Grau, M. Elamin, N. Pender, O. Hardiman (2017)
Clustering of Neuropsychiatric Disease in First-Degree and Second-Degree Relatives of Patients With Amyotrophic Lateral SclerosisJAMA Neurology, 74
C. Bendotti, V. Bonetto, E. Pupillo, G. Logroscino, A. Al-Chalabi, C. Lunetta, N. Riva, G. Mora, G. Lauria, Jochen Weishaupt, F. Agosta, A. Malaspina, M. Basso, L. Greensmith, L. Bosch, A. Ratti, M. Corbo, O. Hardiman, A. Chiò, V. Silani, E. Beghi (2020)
Focus on the heterogeneity of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21
Abstract Amyotrophic Lateral Sclerosis (ALS) is an incurable neurodegenerative condition. Despite significant advances in pre-clinical models that enhance understanding of disease pathobiology, translation of candidate drugs to effective human therapies has been disappointing. There is increasing recognition of the need for a precision medicine approach toward drug development, as many failures in translation can be attributed in part to disease heterogeneity in humans. PRECISION-ALS is an academic industry collaboration between clinicians, Computer Scientists, Information engineers, technologists, data scientists and industry partners that will address the key clinical, computational, data science and technology associated research questions to generate a sustainable precision medicine based approach toward new drug development. Using extant and prospectively collected population based clinical data across nine European sites, PRECISION-ALS provides a General Data Protection Regulation (GDPR) compliant framework that seamlessly collects, processes and analyses research-quality multimodal and multi-sourced clinical, patient and caregiver journey, digitally acquired data through remote monitoring, imaging, neuro-electric-signaling, genomic and biomarker datasets using machine learning and artificial intelligence. PRECISION-ALS represents a first-in-kind modular transferable pan-European ICT framework for ALS that can be easily adapted to other regions that face similar precision medicine related challenges in multimodal data collection and analysis.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration – Taylor & Francis
Published: Jul 3, 2023
Keywords: Precision medicine; scientific collaboration; data science; amyotrophic lateral sclerosis
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.